Gene therapies in the pipeline to treat hemophilia will be very expensive, but they also seem to be very efficacious, and multiple could hit the market between now and 2024, said Ray Tancredi, RPh, MBA, CSP, divisional vice president, specialty pharmacy development and brand Rx/vaccine purchasing, Walgreens.
Gene therapies in the pipeline to treat hemophilia will be very expensive, but they also seem to be very efficacious, and multiple could hit the market between now and 2024, said Ray Tancredi, RPh, MBA, CSP, divisional vice president, specialty pharmacy development and brand Rx/vaccine purchasing, Walgreens.
Transcript
There are a few gene therapies for hemophilia in the pipeline. What will it mean for the health care system if more than one of these expensive therapies is approved in the next 1 to 2 years?
Yeah, that's an interesting thought. When you think of the cell and gene products, you know, I saw 4 therapies for hemophilia A in the pipeline and 2 therapies for hemophilia B. They all have the potential to come to market between now and 2024. All of these products have similar labels upon approval—use limited to moderate to severe disease—and they're really comparable in safety and efficacy. And not only that, these products will really compete with drugs that are already entrenched in the marketplace, like Hemlibra, which is a long-acting factor replacement product.
So, this may create a market where the payers have to create formularies, maybe even have different patient evaluations for prior authorization. And the primary drivers will be: How do the manufacturer and the payers work together to use these products and ensure that that they're effective? I saw some stats in the New England Journal of Medicine; there was an 84% decrease in bleeds and a 99% decrease in factor use for BioMarin's hemophilia product.
So, I think they're efficacious. I don't know exactly what the costs will be, but you know they will be very expensive, and pharma and the payers and plan sponsors are all going to have to look at these therapies, evaluate their efficacy and the costs, and determine the best patients for these products to be used in.
But very exciting. When you think about hemophilia as a disease state, these products could change patients’ lives. So, it's very, very exciting, disruptive to the market, and it'll be great for patients to maybe reduce their use of factor products.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More